Peer-reviewed veterinary case report
Nasal lymphoma in 19 cats treated with radiation and chemo outcomes
By Sfiligoi, Gabriella et al.·Published in Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2007·Veterinary Medical Teaching Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Response of nineteen cats with nasal lymphoma to radiation therapy and chemotherapy.
- Species:
- cat
Plain-English summary
Nineteen cats with nasal lymphoma were treated with radiation therapy and chemotherapy to see how well they responded. All cats received radiation and at least six months of chemotherapy, leading to a median survival time of about 31 months. Most cats showed a good response, with over half remaining free of disease during the follow-up period. However, some cats did experience relapses, indicating that while the treatment was effective, additional studies are needed to improve outcomes. Overall, the combination of therapies provided a favorable prognosis for these cats.
People also search for: cat nasal lymphoma treatment · cat cancer survival rates · radiation therapy for cats with lymphoma
Abstract
The records of 19 cats treated for stage I nasal lymphoma with radiation therapy and chemotherapy were reviewed to determine response to therapy, treatment outcome and possible prognostic indicators. All cats were treated with megavoltage radiation therapy to a total dose ranging from 22 to 48 Gy (median dose = 42 Gy). All cats were prescribed at least 6 months of multiagent chemotherapy. The median progression-free interval for all cats was 945 days (31 months). Two cats did not achieve clinical remission. Of 17 cats evaluable for relapse, 10 (58.8%) were progression free during the entire follow-up period. Four cats (23.5%) suffered local recurrence, while three (17.6%) experienced distant relapse. The median survival time was 955 days (31.4 months). The only variable found to have a significant negative impact on survival was destruction of the cribriform plate before therapy (P= 0.002). The long progression free and survival times reported here indicate that cats with stage I nasal lymphoma treated with aggressive local and systemic therapy can have a favorable outcome when compared with other anatomic forms of lymphoma. Despite strong clinical responses to the multimodality therapy used, the fact that three (17.6%) cats relapsed distantly supports the recommendation that treatment with radiation therapy alone is insufficient until further prospective studies can be performed.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17691642/